RET and medullary thyroid gland carcinoma: For example, in a patient receiving selpercatinib for RET-mutant medullary thyroid carcinoma, the addition of larotrectinib at the time of progression to address the emergence of NTRK fusion in a liquid biopsy analysis led to disease control.